---

市場概況

---

The Global Regenerative Medicine Market is projected to experience substantial growth, with the market size expected to increase from USD 31,037 百万で 2023 米ドルへ 92,951 百万までに 2028. これは年間複合成長率を表します (CAGR) の 24.53% の予測期間中に 2023-2028.

The COVID-19 pandemic is anticipated to have a significant impact on the regenerative medicine market. The increasing number of COVID-19 cases worldwide has positively influenced the market, as mesenchymal stem cells have been identified as a safe and effective treatment approach for COVID-19. A research article published in the scientific journal Aging and Disease titled ‘Mesenchymal Stem Cell Therapy for COVID-19: Present or Future’ supports this claim. In early 2020, より多い 10 projects utilizing stem cells to treat patients with coronavirus pneumonia were registered in the official international registry for clinical trials. しかし, these studies are still in the initial stages. 5月に 2020, the Global Institute of Stem Cell Therapy and Research (GIOSTAR) received approval for a COVID-19 clinical trial using stem cells. さらに, the Ministry of Economy in the United Arab Emirates was granted a patent in May 2020 for the development of promising stem cell therapy for COVID-19 treatment. These advancements in stem cell research related to COVID-19 are expected to drive the demand and growth of the regenerative medicine market.

The growth of the global regenerative medicine market can be attributed to several key factors. まず最初に, there is increasing adoption of stem cell technologies, gene therapies, and tissue engineering. Secondly, advancements in regenerative medicine technology are driving market growth. さらに, government initiatives and clinical trials associated with stem cell research are promoting the expansion of the regenerative medicine market. 例えば, the Indian Council of Medical Research (ICMR) released the National Guidelines for Stem Cell Research (NGSCR) 2月中 2022, which aligns with international guidelines. The Indian government has supported ethical and scientific stem cell research through these guidelines, and the Department of Biotechnology (DBT) has provided funding for various projects in stem cell research. Similar initiatives have been taken by governments in Australia, カナダ, and California to support and fund stem cell research and therapy development.

As of August 26th, 2022, あった 1,868 clinical trials of stem cell therapy registered, と 82 studies specifically focusing on regenerative medicines. This indicates a growing demand for stem cell-based products and regenerative medicines in the market. These clinical trials are predominantly taking place in the United States, ヨーロッパ, そして中国, with increasing support from Canada, 中東, そしてオーストラリア. Various universities, research centers, and companies are primarily targeting indications such as acute lymphoblastic leukemia (ALL), acute megakaryoblastic leukemia (AML), and acute graft versus host disease (AGHD). It is expected that the success rate of these initiatives will gradually increase over the forecast period, driving the growth of the regenerative medicine market.

---

市場セグメンテーション

---

市場はさまざまな要因に基づいて分割されます, including type of technology, 応用, そして地理.

Segmentation by Type of Technology
Stem Cell Therapy
Biomaterial
Tissue Engineering
Other Types of Technologies

アプリケーションごとのセグメンテーション
Bone Graft Substitutes
Osteoarticular Diseases
Dermatology
心臓血管
Central Nervous System
その他の用途

地理によるセグメンテーション
北米 – アメリカ, カナダ, メキシコ, および北米のその他の地域
ヨーロッパ – イギリス, ドイツ, フランス, イタリア, スペイン, ロシア, およびその他のヨーロッパ
アジア太平洋地域 – 中国, 日本, インド, オーストラリア, 韓国, およびその他のアジア太平洋地域
ラテンアメリカ – ブラジル, アルゼンチン, およびその他のラテンアメリカ諸国
中東とアフリカ – 南アフリカ, GCC, およびその他の中東およびアフリカ

Stem Cell Therapy is projected to be the largest segment in terms of technology during the forecast period. In the field of the central nervous system, there has been significant research using stem cells to address various neurological conditions. Human blood and bone marrow stem cells have been extensively used to isolate hematopoietic stem cells (HSCs) for regenerative medicine. Adult stem cells have gained renewed interest as a potential source of undifferentiated stem cells for various applications.

Research on adult stem cells has been driven by their ability to divide indefinitely and generate all cell types of the organ they originate from, potentially regenerating the entire organ from just a few cells. Unlike embryonic stem cells, the production of adult stem cells does not require the destruction of an embryo. Stem cell research has received considerable attention and has been extensively studied in the medical field. Collaborations such as the one between ExCellThera Inc. and Ossium Health, which aims to use adult stem cells from deceased donors, are expected to boost market growth.

Major market players are focusing on strategic initiatives such as product launches and mergers and acquisitions to expand their presence in the market. 例えば, BioCardia’s Covid-19 stem cell therapy trial was approved by the US Food and Drug Administration in April 2022. Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement in October 2022 to develop stem cell-derived programs for hematologic malignancies and solid tumors. Cipla Limited’s partner, Stempeutics Research Pvt. 株式会社, received regulatory approval in August 2020 for the launch of Stempeucel in India, which is indicated for the treatment of certain diseases. These developments in stem cell therapy are expected to drive growth in the market.

North America currently holds the largest market share and is expected to maintain this trend during the forecast period. This can be attributed to the presence of major players, rapid technological advancements, and significant investments in stem cell and oncology research. 米国, 特に, is the largest market in the region. The increasing prevalence of diseases such as cancer and diabetes that can be treated with stem cell therapies contributes to the market’s growth. さらに, regenerative medicine has been identified as the next evolution of medical treatments by the United States Department of Health and Human Services, indicating its potential to revolutionize healthcare. The rising popularity and demand for stem cell therapy are expected to drive the market in the region.

The burden of chronic diseases also presents opportunities for market players. Major companies are focusing on research and development activities to introduce new stem cell therapies and promote the growth of regenerative medicines. 例えば, researchers have identified two drug candidates that may slow down dry age-related macular degeneration using a stem-cell-derived model. The outbreak of COVID-19 has also contributed to the growth of the regenerative medicine market, as research efforts are being directed towards developing therapeutics for the disease. しかし, such research is still in the initial stage. These factors, along with the mentioned developments, are expected to drive market growth in the region during the forecast period.

---

競争環境

---

The global regenerative medicine market is characterized by intense competition. 特に, small-scale companies are actively engaging in mergers with larger counterparts to collaborate on the development of tissue models for research and therapeutic applications. その結果, companies across the industry are making significant investments in innovative technologies, thereby propelling market growth. さらに, it is anticipated that additional players will enter the market in the forthcoming years. 現在, アッヴィ株式会社, Osiris Therapeutics (スミス & Nephew), Integra Lifesciences, Cook Biotech Incorporated, Organogenesis Inc., and Baxter International, とりわけ, hold prominent positions within the market.

Key companies profiled in this report include Cook Biotech Incorporated, Organogenesis Inc., Baxter International, Medtronic Plc, サーモフィッシャーサイエンティフィック, Merck KgaA, ベクトン・ディキンソン・アンド・カンパニー, ノバルティスAG, スミス & Nephew, AbbVie Inc.

---

最近の業界の発展

---

Autolus Therapeutics plc made an announcement in April 2022 regarding the Regenerative Medicine Advanced Therapy (RMAT) designation granted by the U.S. 食品医薬品局 (FDA) to its leading gene therapy, obecabatagene autoleucel. This therapy is a CD19-directed autologous chimeric antigen receptor T (CAR-T) therapy and is currently being investigated in the ongoing FELIX Phase 2 study focused on Leukemia.

六月に 2021, the launch of the RegeneratOR Test Bed took place with the objective of bringing together various resources to advance the field of regenerative medicine in the United States. This initiative aims to foster collaboration and innovation, facilitating the development and progress of regenerative medicine within the country.

---

主な質問への回答

---

What is the duration of the study period for the Global Regenerative Medicine Market?
The Global Regenerative Medicine Market has been studied from 2018 に 2028.

What is the growth rate of the Global Regenerative Medicine Market?
The Global Regenerative Medicine Market is projected to grow at a compound annual growth rate (CAGR) の 24.53% 今後5年間にわたって.

What is the size of the Global Regenerative Medicine Market?
The Global Regenerative Medicine Market is expected to reach USD 31,037 百万で 2023 そして、CAGR で成長すると予測されています。 24.53% 米ドルに到達するには 92,951 百万までに 2028.

Which region has the highest growth rate in the Global Regenerative Medicine Market?
Asia Pacific is experiencing the highest CAGR from 2018 に 2028 in the Global Regenerative Medicine Market.

Which region has the largest market share in the Global Regenerative Medicine Market?
現在 2021, North America holds the highest market share in the Global Regenerative Medicine Market.

Who are the key players in the Global Regenerative Medicine Market?
The major companies operating in the Global Regenerative Medicine Market include Organogenesis Inc., Cook Biotech Incorporated, アッヴィ株式会社, Osiris Therapeutics Inc. (スミス & Nephew), and Integra Lifesciences.